<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02153281</url>
  </required_header>
  <id_info>
    <org_study_id>DETB-071-13</org_study_id>
    <nct_id>NCT02153281</nct_id>
  </id_info>
  <brief_title>Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer</brief_title>
  <acronym>DETB</acronym>
  <official_title>Neuroimaging MAO-B in Medication Free and Treatment Resistant Major Depressive Disorder Using Novel MAO-B Tracer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if monoamine oxidase B (MAO-B) total distribution
      volume (VT), after phenelzine treatment and if so to what extent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive a PET and MRI scan before and after treatment with phenelzine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MAO-B VT levels measured with PET in MDE secondary to MDD</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Phenelzine treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo a PET and MRI scan before and after the treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>phenelzine treatment</intervention_name>
    <description>Subjects will have a PET and MRI scan before and after treatment with phenelzine.</description>
    <arm_group_label>Phenelzine treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years of age

          -  good physical health

          -  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of current
             major depressive episode (MDE)

          -  DSM-IV diagnosis of major depressive disorder (MDD) verified by SCID for DSM-IV and a
             psychiatric consultation

          -  greater than 17 on the 17 item HDRS (Hamilton Depression Rating Scale).

          -  history of non-response to several different antidepressant classes

        Exclusion Criteria:

          -  herbal, drug or medication use (that affect CNS function)

          -  suicide attempts

          -  drug or medication use within eight weeks (+5 half lives of medication)

          -  history of substance abuse or any neurotoxin use

          -  history of psychotic symptoms

          -  history of central nervous system (CNS) medical illness

          -  current substance abuse

          -  test positive on pregnancy test (for women)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey H. Meyer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Imaging Centre, Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.camh.ca/research</url>
    <description>Information about research at the Centre for Addiction and Mental Health</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 28, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2014</study_first_posted>
  <last_update_submitted>May 22, 2019</last_update_submitted>
  <last_update_submitted_qc>May 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Jeff Meyer</investigator_full_name>
    <investigator_title>Head Neurochemical Imaging in Mood Disorders</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Positron Emission Tomography (PET)</keyword>
  <keyword>MAO-B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenelzine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

